Signal detail

News insight

Source-backed analysis, the reasoning behind the signal, and its market context.

STTKBullishEarningsShort Term

High materiality8/10

Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights

StockNews.AIAug 11, 6:15 AM EDT1 source

Trading thesisImportance 8/10

Bullish over the next 6–18 months as Phase 2b Crohn's starts and SL-846 data approach, supported by ample cash into 2029.

AI summary

What happened and why it matters

Shattuck Labs reports Phase 1 SL-325 data showing favorable safety and durable TL1A-DR3 blockade, with a Q3 2026 start planned for RECEPTIVE-CD1 Phase 2b in Crohn's disease. The company also advances SL-846 with an IND-enabling program and a 2027 data readout, while maintaining a robust cash runway into 2029, collectively signaling potential near-term clinical catalysts and longer-term growth optionality in the DR3 axis.

RECEPTIVE-CD1 Crohn's Phase 2b initiation expected in 3Q26.
Phase 1 SL-325 data upgrades DR3/TL1A axis prospects; 3.7% ADA.
SL-846 IND-enabling work with 2027 Phase 1 data potential.
Cash runway extended to 2029 after $86.2M offering and $57.1M warrant proceeds.

Sentiment rationale

Clinical milestones (Phase 2b initiation, data readouts) and a strengthened balance sheet reduce execution risk and extend runway, potentially supporting a re-rating of STTK as pipeline progress compounds with capital efficiency.

Key facts

01
Phase 1 SL-325 shows favorable safety and durable TL1A-DR3 blockade.
02
Antidrug antibodies detected in 3.7% of participants.
03
RECEPTIVE-CD1 Phase 2b Crohn's trial to start in Q3 2026.
04
SL-846 bispecific; initial data expected in 2027.
05
Cash and equivalents reach $208.3M as of 6/30/2026; runway to 2029.

Corporate Developments

Category: Corporate Developments. The release centers on quarterly results, capital updates, and near-term clinical milestones, which collectively drive fundamental and valuation-relevant considerations for STTK's development-stage profile.